Literature DB >> 29849093

The new era of adjuvant therapies for melanoma.

Alexander M M Eggermont1,2, Caroline Robert3,4, Antoni Ribas5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29849093     DOI： 10.1038/s41571-018-0048-5

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  20 in total

1.  Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.

Authors:  Alexander M M Eggermont; Domenico Bellomo; Suzette M Arias-Mejias; Enrica Quattrocchi; Sindhuja Sominidi-Damodaran; Alina G Bridges; Julia S Lehman; Tina J Hieken; James W Jakub; Dennis H Murphree; Mark R Pittelkow; Jason C Sluzevich; Mark A Cappel; Sanjay P Bagaria; Charles Perniciaro; Félicia J Tjien-Fooh; Barbara Rentroia-Pacheco; Renske Wever; Martin H van Vliet; Jvalini Dwarkasing; Alexander Meves
Journal:  Eur J Cancer       Date:  2020-10-05       Impact factor: 9.162

2.  Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.

Authors:  Kenneth F Grossmann; Megan Othus; Sapna P Patel; Ahmad A Tarhini; Vernon K Sondak; Michael V Knopp; Teresa M Petrella; Thach-Giao Truong; Nikhil I Khushalani; Justine V Cohen; Elizabeth I Buchbinder; Kari Kendra; Pauline Funchain; Karl D Lewis; Robert M Conry; Bartosz Chmielowski; Ragini R Kudchadkar; Douglas B Johnson; Hongli Li; James Moon; Zeynep Eroglu; Brian Gastman; Magdalena Kovacsovics-Bankowski; Krishna S Gunturu; Scot W Ebbinghaus; Sama Ahsan; Nageatte Ibrahim; Elad Sharon; Larissa A Korde; John M Kirkwood; Antoni Ribas
Journal:  Cancer Discov       Date:  2022-03-01       Impact factor: 38.272

Review 3.  Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?

Authors:  Alice Indini; Fausto Roila; Francesco Grossi; Daniela Massi; Mario Mandalà
Journal:  Am J Clin Dermatol       Date:  2021-05-25       Impact factor: 7.403

4.  Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety.

Authors:  Caroline A Nebhan; Douglas B Johnson
Journal:  Expert Rev Anticancer Ther       Date:  2021-02-14       Impact factor: 3.627

5.  The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.

Authors:  Paolo A Ascierto; Allison Betof Warner; Christian Blank; Corrado Caracò; Sandra Demaria; Jeffrey E Gershenwald; Nikhil I Khushalani; Georgina V Long; Jason J Luke; Janice M Mehnert; Caroline Robert; Piotr Rutkowski; Hussein A Tawbi; Iman Osman; Igor Puzanov
Journal:  J Transl Med       Date:  2022-05-10       Impact factor: 8.440

Review 6.  Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma.

Authors:  Matilde Monti; Francesca Consoli; Raffaella Vescovi; Mattia Bugatti; William Vermi
Journal:  Cells       Date:  2020-02-11       Impact factor: 6.600

Review 7.  Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer.

Authors:  Kabir A Khan; Florence Th Wu; William Cruz-Munoz; Robert S Kerbel
Journal:  EMBO Mol Med       Date:  2021-06-14       Impact factor: 12.137

8.  Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.

Authors:  Claus Garbe; Ulrike Keim; Stefan Suciu; Teresa Amaral; Thomas K Eigentler; Anja Gesierich; Axel Hauschild; Lucie Heinzerling; Felix Kiecker; Dirk Schadendorf; Rudolf Stadler; Cord Sunderkötter; Thomas Tüting; Jochen Utikal; Uwe Wollina; Christos C Zouboulis; Ulrich Keilholz; Alessandro Testori; Peter Martus; Ulrike Leiter; Alexander M M Eggermont
Journal:  J Clin Oncol       Date:  2020-06-12       Impact factor: 44.544

9.  Serum markers improve current prediction of metastasis development in early-stage melanoma patients: a machine learning-based study.

Authors:  Filippo Mancuso; Sergio Lage; Javier Rasero; José Luis Díaz-Ramón; Aintzane Apraiz; Gorka Pérez-Yarza; Pilar Ariadna Ezkurra; Cristina Penas; Ana Sánchez-Diez; María Dolores García-Vazquez; Jesús Gardeazabal; Rosa Izu; Karmele Mujika; Jesús Cortés; Aintzane Asumendi; María Dolores Boyano
Journal:  Mol Oncol       Date:  2020-06-24       Impact factor: 6.603

10.  The Impact of Targeted Therapy on Intracranial Metastatic Disease Incidence and Survival.

Authors:  Anders W Erickson; Sunit Das
Journal:  Front Oncol       Date:  2019-08-23       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.